PTC Therapeutics (PTCT) Gains as Sarepta's Eteplirsen Approved
- AT&T (T) Agrees to Acquire Time Warner (TWX) for More than $80 Billion - WSJ
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
PTC Therapeutics (NASDAQ: PTCT) gains as Sarepta's eteplirsen gains FDA accelerated approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PTC Therapeutics (PTCT) Commences RG7916 Phase 2 in Type 2/3 SMA Patients with Roche, SMAF
- Cerecor (CERC) Surges with Alkermes (ALKS) Following Positive Depression Trial Results
- Twitter (TWTR) Shares Surge Higher in Late Trading
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!